文献速递临床生化临床免疫质量管理与危急值

脂蛋白(a)分析变异与心血管阈值

Lipoprotein(a) analytical variation and cardiovascular thresholds.
PubMed 文献 · Clin Chem Lab Med · 2026-10-26

所有方法不精密度达5.1%生物学变异要求,但两方法间分类不一致率按EAS阈值达12.4%、按ACC/AHA阈值达17.2%,提示标准化及以nmol/L报告结果的必要性。

要点

  • 六种免疫比浊法Lp(a)检测均达到5.1%不精密度要求。
  • 方法间相关性高,但Bland-Altman平均差值mg/dL为0.4–2.6、nmol/L为0.6–6.5。
  • 按EAS和ACC/AHA阈值,两方法分类不一致率分别高达12.4%和17.2%。

核心结论

  • 六种Lp(a)免疫比浊法相关性可接受,但两方法间存在高达12.4%(EAS)和17.2%(ACC/AHA)的风险分类不一致,标准化及以nmol/L报告结果亟待推进。

研究设计与样本

  • 评估六种自动化免疫比浊法Lp(a)检测(试剂与分析仪组合),结果以mg/dL或nmol/L表示。
  • 不精密度按CLSI EP15-A3方案用厂家质控品评估。
  • 按EAS和ACC/AHA的Lp(a)心血管风险cut-off计算百分比一致性。

主要发现

  • 所有免疫比浊法均达到基于生物学变异的5.1%不精密度要求。
  • 多重比较均呈高度显著相关(p<0.001)。
  • Bland-Altman平均差值绝对值:mg/dL法为0.4–2.6,nmol/L法为0.6–6.5。
  • 两方法间百分比一致性按EAS阈值為87.6–96.6%,按ACC/AHA阈值为82.8–93.8%。

关键数值与推荐

  • 不精密度目标:5.1%(基于生物学变异)。
  • Bland-Altman平均差值:mg/dL法0.4–2.6,nmol/L法0.6–6.5。
  • 百分比一致性:EAS阈值87.6–96.6%,ACC/AHA阈值82.8–93.8%。
  • 分类不一致率:EAS推荐下高达12.4%,ACC/AHA指南下高达17.2%。

临床怎么用

  • 检验科应关注不同Lp(a)检测系统间的分类不一致风险,避免仅凭单一方法结果做心血管风险分层。
  • 推动Lp(a)检测标准化并以nmol/L报告结果,有助于减少方法间差异。

局限性

  • 研究未涉及标准化实施后的前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study was designed to evaluate the analytical performances of six automated immunoturbidimetric lipoprotein(a) (Lp(a)) assays, each corresponding to a combination of a reagent and an analyzer (Binding Site Optilite Lp(a) kit, Diagam Lp(a) reagent on Mindray BS480, Diagam Lp(a) reagent on Roche c502, Randox Lp(a) reagent on IDS-ISYS, Roche Tinaquant LPA2 on Roche c702 and Siemens Atellica CH Lp(a)/Atellica® CH 930) using results expressed in mg/dL or nmol/L. METHODS: Imprecision was assessed on manufacturer controls according to the CLSI EP15-A3 protocol. One hundred and 45 patient serum samples from the cardiology department were assessed to compare each method using Spearman's correlation, Passing-Bablok regression and Bland-Altman analyses. Percent agreement was calculated according to the European Atherosclerosis Society and American College of Cardiology/American Heart Association Lp(a) cut-offs for cardiovascular risk. RESULTS: All immunoturbidimetric methods achieved the desirable imprecision of 5.1 % based on biological variation. Highly significant correlations were found across multiple comparisons (p<0.001). The absolute mean of the difference according to Bland-Altman ranged between 0.4 and 2.6 for Lp(a) assays in mg/dL and between 0.6 and 6.5 for Lp(a) assays in nmol/L. The percent agreement between two assays varied from 87.6 to 96.6 % and from 82.8 to 93.8 % using the EAS or the ACC/AHA thresholds. CONCLUSIONS: Despite acceptable correlation among the six Lp(a) turbidimetric assays, a risk of "misclassifications" between two assays up to 12.4 % with the EAS recommendations and 17.2 % with the ACC/AHA guideline remains a major concern. Standardization of methods, including expression of results in nmol/L is needed.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Bargnoux AS, Aamoum A, Grillet PE, et al. Lipoprotein(a) analytical variation and cardiovascular thresholds. Clin Chem Lab Med. 2026. PMID: 42925485. doi:10.1515/cclm-2026-1481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。